GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million

Core Viewpoint - Alfasigma has secured the rights to develop, manufacture, and commercialize linerixibat, indicating a strategic move to enhance its product portfolio in the pharmaceutical sector [1] Company Summary - Alfasigma will gain exclusive rights related to linerixibat, which may lead to potential growth in revenue and market presence [1]